TNFRSF17 and infection: In this prospective cross-sectional study of individuals with ongoing remission after CAR-T cell therapy for B cell malignancies, we demonstrated that seroprotection for vaccine-preventable infections was comparable to the US population after CD19- but not BCMA-CAR-T cell therapy.